先声、贝达、长春高新等多个创新药获批

医药经济报
Jul 04, 2025

1、国内首个,先声药业苏维西塔单抗获批上市7月3日,先声药业集团旗下创新药子公司先声再明宣布,其在中国开发的新一代VEGF靶向抗体药物恩泽舒®(苏维西塔单抗)于6月30日获国家药监局批准上市,成为国内首个覆盖铂耐药卵巢癌全人群的靶向疗法。该药适应症为联合化疗治疗含铂治疗失败的复发性卵巢癌、输卵管癌或原发性腹膜癌,填补了我国该领域靶向治疗的临床空白。苏维西塔单抗是一种重组人源化抗VEGF单克隆抗体,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10